Insmed INC DEF 14A proxy statements

Insmed Incorporated announces its 2026 Annual Meeting of Shareholders to elect directors, conduct an advisory vote on 2025 executive compensation, and ratify its independent auditor, highlighting significant 2025 commercial and clinical advancements.

Insmed Incorporated has filed a definitive proxy statement with the SEC in preparation for its upcoming annual meeting.

Insmed Incorporated is asking shareholders to approve an amendment to its incentive plan to issue 10 million additional shares, supporting continued growth and employee incentivization.

Insmed Incorporated files a definitive proxy statement with the Securities and Exchange Commission.

Insmed's proxy statement outlines proposals for the upcoming annual meeting, including the election of directors, an advisory vote on executive compensation, ratification of the independent auditor, and approval of an amendment to the incentive plan.